208 related articles for article (PubMed ID: 22029879)
1. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Hamidi SA; Lin RZ; Szema AM; Lyubsky S; Jiang YP; Said SI
Respir Res; 2011 Oct; 12(1):141. PubMed ID: 22029879
[TBL] [Abstract][Full Text] [Related]
2. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
3. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
[TBL] [Abstract][Full Text] [Related]
4. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
5. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
6. Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Pehlivan Y; Dokuyucu R; Demir T; Kaplan DS; Koc I; Orkmez M; Turkbeyler IH; Ceribasi AO; Tutar E; Taysi S; Kisacik B; Onat AM
Inflammation; 2014 Aug; 37(4):1280-8. PubMed ID: 24604341
[TBL] [Abstract][Full Text] [Related]
7. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C
Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032
[TBL] [Abstract][Full Text] [Related]
8. The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Tan XY; He JG
Pathol Res Pract; 2009; 205(7):473-82. PubMed ID: 19232841
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
[TBL] [Abstract][Full Text] [Related]
10. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
[TBL] [Abstract][Full Text] [Related]
11. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.
Sauvageau S; Thorin E; Villeneuve L; Dupuis J
Pulm Pharmacol Ther; 2009 Aug; 22(4):311-7. PubMed ID: 19489130
[TBL] [Abstract][Full Text] [Related]
12. Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.
Schroll S; Arzt M; Sebah D; Stoelcker B; Luchner A; Budweiser S; Blumberg FC; Pfeifer M
Scand J Clin Lab Invest; 2008; 68(4):270-6. PubMed ID: 18612919
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.
Lim KA; Kim KC; Cho MS; Lee BE; Kim HS; Hong YM
Korean Circ J; 2010 Sep; 40(9):459-64. PubMed ID: 20967148
[TBL] [Abstract][Full Text] [Related]
14. Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension.
Panchal J; Jaiswal S; Jain S; Kumawat J; Sharma A; Jain P; Jain S; Verma K; Dwivedi J; Sharma S
Eur J Med Chem; 2023 Nov; 259():115681. PubMed ID: 37515921
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
[TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
17. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
18. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.
Lourenço AP; Roncon-Albuquerque R; Brás-Silva C; Faria B; Wieland J; Henriques-Coelho T; Correia-Pinto J; Leite-Moreira AF
Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1587-94. PubMed ID: 16679394
[TBL] [Abstract][Full Text] [Related]
19. Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Fontoura D; Oliveira-Pinto J; Tavares-Silva M; Leite S; Vasques-Nóvoa F; Mendes-Ferreira P; Lourenço AP; Leite-Moreira AF
Rev Port Cardiol; 2014 Apr; 33(4):213-22. PubMed ID: 24780128
[TBL] [Abstract][Full Text] [Related]
20. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.
Mei Y; Jin H; Tian W; Wang H; Wang H; Zhao Y; Zhang Z; Meng F
Pulm Pharmacol Ther; 2011 Aug; 24(4):386-93. PubMed ID: 21396478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
